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Marfan syndrome (MFS), a relatively common autosomal
dominant hereditary disorder of connective tissue with
prominent manifestations in the skeletal, ocular, and
cardiovascular systems, is caused by mutations in the gene
for fibrillin-1 (FBN1). The leading cause of premature
death in untreated individuals with MFS is acute aortic
dissection, which often follows a period of progressive
dilatation of the ascending aorta. Recent research on the
molecular physiology of fibrillin and the pathophysiology
of MFS and related disorders has changed our
understanding of this disorder by demonstrating changes
in growth factor signalling and in matrix-cell interactions.
The purpose of this review is to provide a comprehensive
overview of recent advances in the molecular biology of
fibrillin and fibrillin-rich microfibrils. Mutations in FBN1
and other genes found in MFS and related disorders will be
discussed, and novel concepts concerning the complex and
multiple mechanisms of the pathogenesis of MFS will be
explained.
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M
arfan syndrome (MFS; MIM 154700) is a
relatively common autosomal dominant
hereditary disorder of connective tissue
with prominent manifestations in the skeletal,
ocular, and cardiovascular systems. MFS is
caused by mutations in the gene for fibrillin-1
(FBN1). Many affected individuals have a char-
acteristic habitus with tall stature, long slender
limbs (dolichostenomelia), arachnodactyly, sco-
liosis, and pectus excavatum or carinatum.
Ectopia lentis affects up to 80% of individuals
with MFS and is almost always bilateral. The
leading cause of premature death in untreated
individuals with MFS is acute aortic dissection,
which follows a period of progressive dilatation
of the ascending aorta. Recent comprehensive
treatments of the clinical aspects of MFS have
been published.
12
A review of the molecular genetics of MFS
appeared in these pages in the year 2000.
3 In the
half decade since then, remarkable progress has
been made in elucidating the molecular anatomy
of both fibrillin and the fibrillin-rich microfibrils
as well as in understanding the molecular
pathogenesis of MFS. Initial ideas about the
pathogenesis of MFS concentrated on a static
dominant negative model based on the concept
of fibrillin-rich microfibrils as purely architec-
tural elements in the extracellular matrix. Recent
findings greatly enhanced our understanding of
the pathogenesis of MFS by demonstrating
changes in growth factor signalling and other
changes in matrix-cell interactions, which has
set the stage for attempts to develop novel forms
of treatment.
The current review will focus on the fibrillin-
LTBP gene family and tissue organisation of
microfibrils, mutations in genes associated with
MFS and related phenotypes, the structure of
fibrillin-1 domains, FBN1 mutations and proteo-
lysis, and the genetics of MFS in mouse models.
The current review will highlight advances
published after the first review; interested read-
ers are referred to the previous article for more
information on other topics.
3
THE FIBRILLIN-LTBP GENE FAMILY
The fibrillins and the latent-TGFb-binding pro-
teins (LTBPs) form two closely related protein
families with structural and non-structural func-
tions in the extracellular matrix. Both families
are characterised by a modular domain structure
with repeated cysteine-rich modules.
Members of the fibrillin-LTBP family have
both structural and non-structural functions.
Three closely related fibrillins have been
described. Fibrillin-2
4 and the recently discovered
fibrillin-3
5 have a domain organisation identical
to that of fibrillin-1 and an overall level of amino
acid identity of between 61% and 69%. Several
lines of evidence suggest that the fibrillins have
both overlapping and unique functions.
56 All
three fibrillins are structural components of
Abbreviations: BMP, bone morphogenetic protein;
cbEGF, calcium binding epidermal growth factor; CCA,
congenital contractural arachnodactyly; CMN, cystic
medial necrosis; CSGE, conformation sensitive gel
electrophoresis; DHPLC, denaturing high performance
liquid chromatography; EBP, elastin-binding protein;
ECM, extracellular matrix; HNPCC, hereditary non-
polyposis colorectal cancer; LAP, latency-associated
peptide; LDS, Loeys-Dietz aortic aneurysm syndrome; LLC,
large latent complexes; LTBP, latent-TGFb-binding protein;
MAGP-1, microfibril-associated glycoprotein-1; MFS,
Marfan syndrome; MFS2, type 2 Marfan syndrome;
MMP, matrix metalloproteinase; MMR, mismatch repair;
MSI, microsatellite instability; NMR, nuclear magnetic
resonance; PTC, premature termination codon; SSCP,
single stranded conformation polymorphism; TAAD,
thoracic ascending aortic aneurysms and dissections;
TbRII, type II TGFb receptor; TGFb, transforming growth
factor-b; UMD, Universal Mutation Database; WMS,
Weill-Marchesani syndrome
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457 ; however, fibrillin-2 and fibrillin-3 are pre-
ferentially expressed in embryonic developmental stages,
458
whereas fibrillin-1 is expressed from the gastrula to
throughout adult life.
9 In addition, distinct phenotypes are
observed in fbn1 and fbn2 gene targeting experiments in mice;
since microfibrils are assembled in both mice, some overlap
of architectural functions appears likely.
5 10–12
The LTBPs associate with transforming growth factor-b
(TGFb), thereby regulating its secretion and spatial and
temporal activation; in humans, four members of the LTBP
family are known, three of which undergo alternative
splicing.
13 TGFb is synthesised as a homodimeric proprotein,
whereby the dimeric propeptide is cleaved intracellularly
from the growth factor; the propeptide is called the latency-
associated peptide (LAP) because TGFb cannot bind to its
surface receptors when it is bound to the LAP. The LAP in
turn is usually disulfide-bonded to an LTBP; this aggregate is
referred to as the large latent complex (LLC). The LTBPs thus
have a dual function: as structural components of the
extracellular matrix and as modulators of TGFb availability
(the reader is referred to Rifkin
14 and Todorovic et al
15 for
recent reviews on this topic).
The fibrillins and LTBPs display a remarkably similar
domain structure made up of repeated cysteine-rich struc-
tural modules including multiple copies of an epidermal
growth factor-like module (EGF) and an 8-cysteine (8-Cys)
module found only in the fibrillins and LTBPs (fig 1). EGF
modules are approximately 45 residues in length and are
characterised by six conserved cysteine residues that form
three intramodule disulfide bonds. Forty three of the 47 EGF
modules in fibrillin-1 and many of those in the various LTBPs
additionally conform to a consensus sequence, (D/N)-X-(D/
N)(E/Q)Xm(D/N)*Xn(Y/F), that mediates calcium binding in
the N-terminal region of the module (m and n are variable,
and an asterisk denotes b-hydroxylation).
16
The 8-Cys module (also variously referred to in the
literature as the 8-cysteine module, the TB module, or the
LTBP module) occurs only in the fibrillins and LTBPs. An
experiment using a recombinant construct of one of the
seven 8-Cys modules of fibrillin-1 showed that the structure
is stabilised by four intradomain disulfide bonds.
17 Some
8-Cys domains can mediate binding to the LAP-TGFb
complex.
18 19 Not all domains have this function; a recent
study showed that LTBP1 and LTBP3 bound efficiently to
TGFb, LTBP4 bound weakly, and LTBP2 and fibrillin-1 and
fibrillin-2 did not bind.
20 An additional cysteine-rich module
with similarities to both the cbEGF module and the 8-Cys
module, termed the 8-Cys hybrid module,
21 can mediate
intermolecular disulfide bonding between fibrillin-1 mono-
mers, which may be an important step in the assembly of
microfibrils.
22 The fibrillins share a globular C-terminal
domain of about 120 residues with the fibulins
23;i n
fibrillin-1, this module may be involved in homotypic
interactions.
24
TISSUE ORGANISATION OF MICROFIBRILS
Fibrillin microfibrils are widely distributed extracellular
matrix multimolecular assemblies comprised of fibrillin and
other proteins. The microfibrils endow elastic and non-elastic
connective tissues with long range elasticity. They direct
tropoelastin deposition during elastic fibrillogenesis and form
an outer mantle for mature elastic fibres. Microfibril arrays
are also abundant in dynamic tissues that do not express
elastin, such as the ciliary zonules of the eye. Analysis of
fibrillin-rich microfibrils by transmission electron microscopy
has revealed them to have a diameter of 8–12 nm, a tubular
appearance, and beaded periodicity, and to contain glyco-
proteins. Isolated fibrillin-rich microfibrils have a complex
‘‘beads on a string’’ appearance, and are extensible.
Fibrillin–1 P
Fibrillin–2 G
Fibrillin–3 PG
LTBP–1
LTBP–2
LTBP–3
LTBP–4
G
PG
P
N-terminal
4-cys P
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C-terminal
Figure 1 The fibrillin-1 gene FBN1 spans about 235 kb of genomic DNA on chromosome 15q21.1, and has a transcript size of 9749 nucleotides; the
coding sequence of FBN1 is spread over 65 exons,
21 and three alternatively spliced non-coding 59 exons have been described.
249 With several
exceptions, single exons code for the domains in fibrillin-1 as shown here.
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parallel alignment. These bundles adopt tissue-specific
architectures that are dictated by cells, and by the strength
and direction of forces put upon the tissue. They are found in
locations that are subject to repeated mechanical stresses,
and in the proximity of basement membranes, and they serve
a critical biomechanical anchoring role in dynamic connec-
tive tissues.
25
Elastic fibre formation is a developmentally regulated
process in which tropoelastin (the soluble precursor of
mature elastin) is deposited on a preformed template of
fibrillin microfibrils.
26 Mature elastic fibres are a composite
biomaterial with an outer microfibrillar mantle and an inner
core of amorphous cross-linked elastin with some embedded
microfibrils. The proportion of microfibrils to elastin appears
to decline with age, with adult elastic fibres often having only
sparse peripheral mantles of microfibrils.
A recent investigation by mass spectrometry of the
composition of purified fibrillin-rich microfibrils from non-
elastic and elastic tissues showed that in all microfibril
preparations, fibrillin-1 was abundant and the only fibrillin
isoform detected. Isolated microfibrils, extracted from tissues
by enzyme digestions or homogenisation, have a ‘‘beads on a
string’’ appearance with untensioned periodicity of
,56 nm.
27 28 Unextracted hydrated zonular microfibrils
appeared, by quick freeze deep etch microscopy, to be more
tubular, suggesting that molecular components are lost or
that there is a major molecular rearrangement on extrac-
tion.
29 The molecular basis of the ‘‘beads’’, and fibrillin-1
alignment in microfibrils remain unclear.
Models of fibrillin-1 alignment
The details of the precise molecular architecture of fibrillin-1
alignment within microfibrils are not entirely clear, and
several models have been proposed. An intermolecular
fibrillin-1 transglutaminase cross-link
30 provides molecular
constraints, although mass spectrometry has shown that not
all fibrillin-1 molecules within tissue microfibrils are cross-
linked.
31
The ‘‘hinge’’ model, based on detailed scanning transmis-
sion electron microscopy, mass mapping, automated electron
tomography, and atomic force microscopy data,
28 32–34 predicts
maturation from an initial parallel head to tail alignment to
an approximately one third stagger (,100 nm) that would
allow transglutaminase cross-link formation, and further
packing into a more energetically favourable ,56 nm
untensioned form.
The one third staggered model was suggested on the basis
of extrapolation of molecular dimensions,
35 the crystal
structure of fibrillin-1 cbEGF/TB/cbEGF domain arrays,
36
and calcium binding studies of TB/cbEGF flexibility.
37
Interested readers can find further discussion of issues
surrounding fibrillin-1 alignment and microfibrillar architec-
ture in Baldock et al,
28 Davis et al,
29, Kielty et al,
34 and Lee et al.
36
Early studies of isolated microfibrils revealed a number of
highly stretched microfibrils with periodicities up to
,150 nm, which suggested that microfibrils may have elastic
properties.
27 Stretching of isolated intact microfibrils has been
achieved using surface tension forces and molecular comb-
ing.
33 These studies showed that microfibrils behave as
relatively stiff elastic filaments which can perform anchoring
roles in ciliary zonules and other basement membrane
interfaces. It was confirmed by x ray diffraction that hydrated
microfibril bundles are elastic, and suggested that elasticity
in microfibril-rich tissues may arise, in part, from reversible
alterations in supra-microfibrillar arrangements. Proteolytic
damage to microfibrils that may occur in MFS or ageing, may
generate stretched microfibrils that may have lost their elastic
properties.
25 38
ASSEMBLY OF MICROFIBRILS
Today, a fragmented picture has emerged of the events and
molecules involved in the assembly process from profibrillins
to mature tissue microfibrils. The mechanisms include
profibrillin processing, self-assembly, regulatory events,
cross-link formation, and maturation of microfibrils.
Microfibril assembly in individuals with MFS
Early immunofluorescence studies with dermal fibroblasts or
skin biopsies obtained from individuals with MFS showed
reduced or qualitatively altered fibrillin networks as com-
pared to controls.
39–41 However, such altered patterns were not
observed in all samples.
41 42 One possible interpretation of
these data is that a subset of mutations in fibrillin-1
compromises the assembly process and thus the formation
of microfibril networks. Further evidence for this interpreta-
tion comes from pulse chase experiments using dermal
fibroblasts from individuals with MFS. These analyses
showed deficiencies at different levels such as fibrillin
synthesis and secretion, as well as deposition into the
extracellular matrix.
43 44 Despite the differences in the
secreted amount of fibrillin, a large portion of the fibroblasts
studied showed impaired incorporation of the mutant
fibrillin into the extracellular matrix, suggesting functional
disturbances in early stages of the assembly mechanism.
45 46
In cases where higher order assembly into beaded micro-
fibrils was observed, the ultrastructural appearance showed
several types of abnormalities including diffuse, frayed, or
poorly defined interbead domains, or variable interbead
periodicities.
47–49 These consequences potentially could also
emerge from functional problems in the assembly mechan-
ism. In summary, although molecular evidence is still
lacking, it seems clear that a certain subset of mutations in
fibrillin-1 leading to MFS and other microfibrillopathies
directly affects microfibril assembly mechanisms.
Role of propeptide processing in fibrillin assembly
Fibrillins are phylogenetically old proteins occurring in
species from jellyfish to human. All known fibrillins possess
highly conserved basic recognition sites (RX(K/R)R) for
processing by endoproteinases of the furin/PACE type within
the unique N- and C-terminal domains. It has been shown by
several groups and methodologies that fibrillin-1 is indeed
processed at these recognition sites.
22 50–54 Processing pro-
duces a 17 or 20 residue N-terminal propeptide depending on
the actual cleavage site for the signal peptide, and a 140
residue C-terminal propeptide. Due to the size of the
propeptide, C-terminal processing is accessed much better
experimentally and thus has received more attention. For
fibrillin-1, it has been demonstrated that processing of the C-
terminal propeptide is required for deposition into the
extracellular matrix, suggesting that profibrillin-1 conversion
to mature fibrillin-1 plays a regulatory role in assembly into
higher order aggregates.
43 50 53 On the molecular level, it is not
clear how the presence of a C-terminal propeptide prevents
matrix deposition and assembly. The propeptide may interact
and mask self-assembly sites in fibrillin-1.
24 A mutation in
fibrillin-1 (R2726W) associated with isolated skeletal fea-
tures of MFS was shown to interfere with normal processing
at the C-terminal end and thus disturbed the incorporation of
the mutated protein into the extracellular matrix.
50 Other
mutations close to processing sites may have similar
consequences. Virtually no information is available as regards
the functional role of the N-terminal processing. However, by
analogy, it is predicted that the N-terminal propeptide also
regulates assembly of fibrillins.
Self-assembly of fibrillins
As described in the ‘‘Tissue organisation of microfibrils’’
section, the molecular organisation of fibrillin-1 in microfibrils
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of different models for the alignment of fibrillin in
microfibrils.
72 83 03 53 65 1 Despite the differences in these
models in terms of stagger and molecular condensation of
individual molecules, common to all models is a head to tail
orientation of fibrillin-1 molecules as originally proposed by
Sakai and coworkers in 1991.
7 Another commonly accepted
property of microfibrils is the involvement of six to eight
fibrillin molecules per cross-section of the interbead
region.
28 55 56
Correlation of antibody epitopes in the fibrillin-1 molecule
with the location of the corresponding epitopes in micro-
fibrils clearly revealed that the terminal ends of the fibrillin
molecules are situated in or close to the beads.
72 85 1 Data
obtained with recombinant fibrillin-1 fragments have estab-
lished direct interaction in a homotypic N- to C-terminal
fashion.
57 These results established a linear head to tail self-
assembly mechanism for fibrillin-1. Heterotypic interactions
between fibrillin-1 and fibrillin-2 in an N- to C-terminal
fashion suggested that both fibrillin isoforms can be
organised within the same microfibril,
57 and colocalisation
of both isoforms has indeed been demonstrated by double
immunogold labelling in tissue microfibrils.
8 Electron micro-
scopy after rotary shadowing of full length recombinant
fibrillin-1 suggested that the interaction epitopes are rela-
tively close to the terminal ends.
57 These results were further
substantiated by analyses of smaller overlapping fibrillin-1
fragments in various ligand interaction assays, positioning
the interaction sites in the N-terminal region encoded by
exons 1–8 and the C-terminal region encoded by exons 57–
65.
24
In addition to a linear head to tail self-interaction, there is
evidence that lateral homotypic interactions also play a role
in fibrillin assembly. Reducible homodimer formation early
during biosynthesis was observed for recombinant fragments
of fibrillin-1 and -2 spanning from the proline and glycine-
rich domains, respectively, to the second 8-Cys/TB domain,
58
as well as for smaller recombinant fragments of the proline-
rich region of fibrillin-1 and the glycine-rich region of
fibrillin-2 including flanking domains.
59 Additionally, homo-
typic lateral interactions have been observed with an N-
terminal recombinant fibrillin-1 fragment encoded by exons
1–8, as well as with an C-terminal fragment encoded by
exons 57–65.
24 The lateral homotypic interactions between N-
terminally and C-terminally located fragments as well as the
head to tail linear interactions between the N- and C-
terminal ends are of high affinity with dissociation constants
in the low nanomolar range, indicating that both types of
mechanisms are highly relevant for initial assembly
stages.
24 57
Intermolecular cross-link formation in fibrillin
assembly
Two types of intermolecular cross-links important for the
stability of microfibrils have been identified: reducible
disulfide bonds and non-reducible e(c-glutamyl)lysine
cross-links. Intermolecular disulfide bond formation is
apparent early in the assembly of microfibrils since higher
molecular weight disulfide-bonded aggregates containing
fibrillin can be observed after a few hours in cell or organ
cultures.
22 60 Most of the highly conserved cysteine residues in
fibrillins are predicted to stabilise individual domains
through intramolecular disulfide bonds.
17 35 36 One cysteine
residue in the first hybrid domain of human fibrillin-1 and -2
has been shown to be available for intermolecular cross-links
on the surface of the molecule.
22
Additional data suggest that other cysteine residues, which
are normally involved in intramolecular domain stabilisation,
may be reshuffled to participate in intermolecular cross-links.
Cysteine residues in the first and second 8-Cys/TB domain
have been suggested for such a role based on the propensity
of various recombinant fibrillin-1 and -2 fragments to form
reducible homodimers.
58 59 Such a mechanism would likely
require the enzymatic activity of one or more protein
disulfide isomerases on the cell surface or in the extracellular
matrix.
Non-reducible e(c-glutamyl)lysine cross-links, catalysed by
transglutaminases, have been identified in microfibrils
extracted from various tissues.
30 61 62 Detailed analyses of
microfibrils from human tissues have identified transgluta-
minase cross-links in the N- and C-terminal regions of
fibrillin-1, as well as a high overall content of these cross-
links.
30 In addition to fibrillin-1, another prominent protein
in microfibrils, microfibril-associated glycoprotein-1 (MAGP-
1), was also characterised as a substrate for transglutami-
nase.
63 It is possible that besides homotypic fibrillin-1
transglutaminase cross-links, heterotypic fibrillin-1-MAGP-
1 cross-links may be present in microfibrils. Zonular fibres in
the eye have been demonstrated to be a target for
transglutaminase 2.
64 Biomechanical analyses of microfibrils
suggested that transglutaminase cross-links play an impor-
tant role in strengthening the microfibrils.
65 Other potential
roles of the transglutaminase cross-links may include correct
lateral alignment of fibrillin or other molecules as a
prerequisite for downstream assembly events. Mutations
disrupting transglutaminase cross-link sites likely result in
serious consequences for microfibril assembly and stability.
To gain insight into such potential mechanisms in MFS and
other microfibrillopathies, it will be important to identify the
exact amino acid residues involved and the time course of
transglutaminase cross-link formation.
Accessory molecules important for fibrillin assembly
In addition to self-assembly and cross-linking mechanisms,
other molecules may be involved in the assembly process of
microfibrils. Several regions in fibrillin-1 have been identified
as interacting with heparin/heparan sulfate with high
affinity.
66–68 In cell culture assembly assays, these glycosami-
noglycans inhibit the formation of microfibrillar net-
works,
66 67 leading to the hypothesis that heparan sulfate or
heparan sulfate containing proteoglycans may have regula-
tory functions in the assembly of microfibrils. Recently, the
heparan sulfate containing proteoglycan perlecan was iden-
tified as a molecule which interacts with fibrillin-1 and with
microfibrils close to basement membrane zones.
69 Reduced
amounts of microfibrils in basement membrane zones of
perlecan null mice may reflect a potential role for perlecan in
microfibril assembly.
69
MICROFIBRIL-ASSOCIATED PROTEINS
In addition to fibrillin, several other proteins are integral
components of the microfibrils or associated with them. These
can be grouped into small non-fibrillin proteins that are
integral parts of fibrillin-rich microfibrils (table 1) and proteins
that can associate with fibrillin-rich microfibrils but do not
serve an integral structural function (table 2). We will not
attempt a comprehensive review of the non-fibrillin proteins
but rather will summarise the most important functions that
have been attributed to these proteins and their interaction
with fibrillin. Readers are referred to Gibson
70 and the
references in the tables 1 and 2 for further information. It
appears likely that more interacting proteins remain to be
discovered in light of a recent proteomics study of fibrillin-rich
microfibrils showing copurification of a number of proteins in
addition to fibrillin-1. For instance, c-crystallin copurified with
zonular microfibrils, suggesting an interaction that could
contribute to zonule anchorage to the lens.
31
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One role of non-fibrillin microfibrillar proteins is as structural
constituents of the microfibrils. For instance, microfibril-
associated glycoprotein-1 (MAGP-1) is a small glycoprotein
with an apparent molecular weight of 31 kDa that is covalently
bound to microfibrils by disulfide linkages
71 and is specifically
located on the beads of the beaded-filament structure of the
microfibrils.
72 MAGP-2 has a more restricted tissue distribution
than MAGP-1,
73 suggesting it may have tissue- or develop-
mental stage-specific functions. MAGP-1 and MAGP-2 bind to
distinct regionsof fibrillin-1 and it has been suggested that this
may help to regulate microfibrillar assembly.
74
Interaction with other matrix components
Interactions between fibrillin-rich microfibrils and tropoelas-
tin are important for the formation of elastic fibres. In
addition to interactions between fibrillin-1 and tropoelastin,
75
MAGP-1 interacts with tropoelastin
76 77 in a way that is
important for tropoelastin deposition.
78 Microfibrils interact
with a variety of other extracellular matrix structures and
some of these interactions are mediated by non-fibrillin
proteins. For instance, MAGP-1 binds to the a3 chain of type
VI collagen. Since type VI collagen microfibrils and fibrillin-
rich microfibrils are often found near to one another in some
extracellular matrices, it is plausible that MAGP-1 may
mediate a molecular interaction between type VI collagen
microfibrils and fibrillin-containing microfibrils.
79
Interaction with cells
It has become increasingly clear that fibrillin-rich microfibrils
have functions that are not directly related to structural
integrity but rather have to do with growth factor metabolism
and triggering cellular signals. As will be discussed in more
detail below, the latent transforming growth factor-b binding
proteins (LTBP) are a family of secreted glycoproteins, three
of which play an important role in the regulation of TGFb
regulation.
15 In addition to TGFb, microfibrils could con-
ceivably be involved in the regulation of other growth factors,
although little experimental evidence is available at this
point.
14 MAGP-2 can interact with Jagged1 and induce its
shedding; it is thus conceivable that MAGP-2 may be able to
modulate the Notch signalling pathway.
80 There is evidence of
interaction between fibrillin-1 and at least one bone
morphogenetic protein (BMP),
81 82 and fibrillin-2-rich micro-
fibrils and BMP-7 have been shown to functionally interact
in the regulation of limb patterning in a mouse model.
12
Finally, an interesting area of research is the question
whether novel cell signalling pathways are triggered in
MFS or other diseases of the microfibrils, and whether
fragments of the proteins of the microfibrils can acquire
novel signalling properties through exposure of otherwise
cryptic binding sites, a phenomenon that has been well
described in several other disorders such as osteoarthritis.
83
As will be discussed below, there is evidence that fibrillin
fragments can induce matrix metalloproteinase (MMP)
expression, and it is well known that elastin fragments can
induce MMP expression.
84 85
Enzymatic activity
The enzyme lysyl oxidase, which is involved in the cross-
linking of tropoelastin monomers, has been localised to the
interface between extracellular bundles of amorphous elastin
and the microfibrils.
86 Although there is no evidence of a
direct interaction between fibrillin and lysyl oxidase to date,
it is plausible that interactions with fibrillin or other
microfibrillar components might be important for elastogen-
esis.
70 Interestingly, ADAMTS10,
87 an extracellular matrix
protease, is mutated in the autosomal recessive form of Weill-
Marchesani syndrome (WMS).
88 The dominant form of WMS
is caused by mutations in fibrillin-1, suggesting, perhaps, a
potential interaction between ADAMTS10 and fibrillin-1.
Table 1 Small non-fibrillin proteins that are integral
parts of fibrillin-rich microfibrils in at least some tissues
and developmental stages
Protein Chromosome Potential functions
MAGP-1 1p36.1–p35 Tropoelastin deposition
78
Tropoelastin binding
76 89
Binding to fibrillin-1
76 90
Binding to fibrillin-2
91
Ternary complex with
tropoelastin and biglycan
77
Posttranslational modifications
92
Ternary complex with
tropoelastin and decorin
93
Binding to type VI collagen
79
Substrate for transglutaminase
63
MAGP-2 12p12.3–p13.1 Binding to fibrillin-1
74 90
Binding to fibrillin-2
74
RGD-mediated cell attachment
94
Interaction with Jagged1
80
AAAP-40 5q32–q33.2 40 kDa protein
95 96
(MAGP-3)
MFAP1 (AMP) 15q15–q21 54 kDa protein that is processed
to a 36 kDa protein
97 98
MFAP3 5q32–q33.1 41 kDa serine-rich protein
99
MFAP4 17p11.2 Colocalisation to elastic fibres
100
(MAGP-36) Role in elastogenesis
101
Table 2 Proteins that can associate with fibrillin-rich microfibrils but do not serve an integral structural function in them
Protein Class of protein Potential biological role of interaction
Elastin – Tropoelastin deposition
78
Regulation of microfibril formation
75
LTBP-1 Fibrillin-LTBP Sequestering of latent TGFb
102
LTBP-2 Fibrillin-LTBP Structural role?
103
LTBP-4 Fibrillin-LTBP Sequestering of latent TGFb
102
Versican Proteoglycan (hyalectin) Link fibrillin-microfibrils to versican/hyaluronan network
104
Perlecan Proteoglycan (hyalectin) Anchoring microfibrils to basement membranes and in the
biogenesis of microfibrils
69
Heparin/heparan sulfate Proteoglycan Binding of related heparan sulfate chains may regulate cell-surface
assembly of fibrillin
66
Decorin Small dermatan sulfate proteoglycan Induction of fibrillin-1 expression in renal fibroblasts and mesangial cells
105
Biglycan Small dermatan sulfate proteoglycan Role in elastogenesis
77
Fibulin-2 Fibulin Mediate/modulate attachment of fibrillin to tropoelastin
106
Fibulin-5 Fibulin Regulation of the initial deposition of tropoelastin on to microfibrils
107
BMP-7 Bone morphogenetic protein Regulation of limb patterning
12
EMILIN-1 Elastin-microfibril interface located proteins Role in elastinogenesis
108
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potential functions of this molecule remain to be elucidated.
Mutations in FBN1, FBN2, and other genes associated
with MFS and related phenotypes
Mutations in FBN1 were discovered in individuals with MFS
in 1991,
109 and subsequently mutations in FBN2 were
discovered in individuals with a phenotypically related
disorder, congenital contractural arachnodactyly (CCA).
110
More recently, mutations in the genes for TGFBR1 and
TGFBR2 were found in several disorders with varying degrees
of overlap with classic MFS.
111–113 Genetic loci for other forms
of isolated aortic dilatation and dissection have been
identified. The identification of mutations in these genes
has provided significant insight into the pathogenetic path-
ways involved in MFS and related disorders, and further
insight is to be expected from characterising the full
spectrum of mutations associated with these disorders and
from identifying the full set of genes in which mutations
cause related disorders of connective tissue. The following
sections present the current state of knowledge on FBN1,
FBN2, and TGFBR2 mutations and on loci involved in isolated
aortic aneurysm and dissection.
MUTATION ANALYSIS OF THE FBN1 GENE IN
INDIVIDUALS WITH MFS: SENSITIVITY, METHODS,
AND CLINICAL INDICATIONS
In most instances, the diagnosis of MFS can be made on
clinical grounds. A set of clinical diagnostic criteria, as
summarised in the Ghent nosology,
114 define major criteria
with high diagnostic specificity and minor criteria with less
specificity. In order to make a diagnosis of MFS, the Ghent
nosology requires a combination of major criteria in at least
two organ systems and involvement of a third organ system.
In the majority of cases, these criteria allow the establish-
ment or exclusion of the diagnosis. However, the interpreta-
tion of these criteria is not always obvious for a number of
reasons. Firstly, MFS is known for its extensive phenotypic
variability both within and between families, which may
cause underdiagnosis of the condition.
115 Secondly, establish-
ing a diagnosis of MFS in children can be difficult because
several manifestations of MFS are age-dependent and may
not yet be present in childhood. Thirdly, clinical overlap
exists between MFS and other, so called Marfan-like
conditions which share some of the features of MFS but do
not necessarily have the same outcome.
Therefore, if the Ghent criteria are fulfilled, then the
diagnosis of MFS is certain. In adult patients presenting with
a small number of non-specific skeletal manifestations often
seen in MFS, the diagnosis is unlikely, but a full clinical
evaluation including echocardiography and ophthalmologic
examination is indicated.
In situations of clinical uncertainty, molecular analysis of
the FBN1 gene therefore seems a logical aid to the clinical
diagnosis of MFS. In practice, however, the large and
complex structure of the FBN1 gene and the wide scope of
FBN1 mutations have hampered clinical implementation of
FBN1 testing. Moreover, literature data show great variation
in detection rates of FBN1 mutations and methodologies
used. This can be accounted for by a variety of factors such as
the type of mutational analysis method, the substrate
(genomic versus cDNA) and, most importantly, the accuracy
of the clinical diagnosis. The studies that have looked at the
sensitivity and specificity of FBN1 mutation analysis show
substantial differences in one or several of these factors.
The first mutational studies, performed on cDNA, showed
low efficiency of FBN1 mutation detection using SSCP (single
stranded conformation polymorphism) and yielded mutation
rates of 9% to 23%.
116 117 Subsequent studies, using genomic
DNA as template for analysis of the 65 individual exons of the
FBN1 gene, obtained higher detection rates but varied
according to the type of screening method used.
118–120
Initially the best results were obtained with CSGE (con-
formation sensitive gel electrophoresis), with detection rates
ranging from 57% to 90%.
42 121 122 Subsequent studies have
shown that mutation detection by DHPLC (denaturing high
performance liquid chromatography) is highly efficient,
123
although a relatively high false-positive rate may be an
issue.
124 It now appears that DHPLC is the most efficient
approach for mutation detection also because of its potential
for automation when combined with robotic PCR.
The most important factor influencing the mutation
detection rate appears to be the clinical homogeneity or
heterogeneity of the patient population. Indeed, several
studies have shown that the incidence of FBN1 mutations
is significantly higher in patients who fulfil the MFS
diagnostic criteria than in patients who do not. In a large
study including a cohort of 94 MFS patients and 77 patients
with MFS related phenotypes, Loeys et al
125 found FBN1
detection rates of 66% versus 5%, respectively. They demon-
strated that fulfilling the clinical diagnosis of MFS in itself is
a good predictor of the outcome of FBN1 mutation analysis.
Katzke et al
120 supported these findings by their study which
showed a much higher incidence of mutations in a group of
MFS patients versus those with an MFS related condition,
and concluded that clinical overdiagnosis is the most
important explanation for low FBN1 mutation detection
rates. Two other studies
123 126 also showed that the majority of
patients in whom an FBN1 mutation was found, met the
clinical diagnosis of MFS, supporting the opinion that the
robustness of selection criteria is the most important
determinant of the outcome of mutational studies.
Several clinical situations can occur in which molecular
studies of the FBN1 gene may be helpful. In patients who
present with skeletal, cardiovascular, and/or possibly other
manifestations of MFS but have no involvement of the ocular
system, it can be difficult to establish the diagnosis strictly on
clinical grounds, particularly in the absence of a positive
family history. Here, however, MRI studies can reveal the
presence of dural ectasia in which case the diagnostic criteria
may still be met. Several mutational studies which report
FBN1 mutations in Marfan-like patients have not verified the
presence or absence of dural ectasia, so that the possibility
remains that the diagnostic criteria are in fact met. In cases
where no definitive conclusion can be reached with the
clinical data, molecular analysis of the FBN1 gene is an
alternative option.
Because of the evolving nature of the phenotype, particu-
larly so for the cardiovascular and skeletal manifestations,
children with suspected MFS may not yet fulfil the diagnostic
criteria. In those instances, it is better to postpone a final
diagnosis until later. The identification of an FBN1 mutation
in children or young adults not (yet) fulfilling the diagnostic
criteria can help to identify those who need to be clinically
followed with particular attention.
FBN1 mutations have been identified in a range of
phenotypes, the type 1 fibrillinopathies, with greater or lesser
degrees of clinical overlap with MFS (table 3). A decision as to
whether mutation analysis is indicated when such phenotypes
are suspected needs to be made on an individual basis.
In addition to the more or less well delineated disorders
listed in table 3, FBN1 mutations can be found in individuals
with Marfan-like disorders who do not fulfil the criteria of
the Ghent nosology.
127 It is recommend that accepted clinical
guidelines for the care and management of MFS are applied
in these cases even if the criteria of the Ghent nosology are
not fulfilled, because it is possible that complications such as
aortic dilatation can emerge at any age.
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prenatal or preimplantation diagnosis for prospective parents.
This is one option for which requests appear to be steadily
increasing.
In summary, after stringent clinical selection, a detection
rate of up to 90% is currently achievable in FBN1 molecular
testing of patients with classic MFS.
128 This allows the
implementation of mutational studies in clinical practice.
THE UMD FBN1 DATABASE: A DATABASE FOR FBN1
MUTATIONS IMPLICATED IN MFS AND RELATED
PHENOTYPES
The UMD FBN1 database (http://www.umd.be) was created
in 1995 in an effort to standardise the information regarding
FBN1 mutations using UMD (Universal Mutation Database)
software.
143–149 The database follows the guidelines on
mutation databases of the Hugo Mutation Database
Initiative including nomenclature of mutations.
150
The mutation records of the database include point
mutations, large and small deletions, insertions, and splice
mutations in the FBN1 gene. Each record contains the
molecular and clinical data for a given mutation in a
standardised, easily accessible, and summary form; if
available, data on fibrillin protein biosynthesis classification
groups
45 are included.
To date, 601 FBN1 mutations are available online. The
mutations are spread throughout almost the entire gene
without obvious predilection for any given region.
Approximately 12% of mutations are recurrent.
149
The mutation studies performed to date generally have
concentrated on screening the 65 coding exons of FBN1. For
the most part, methods capable of detecting larger deletions
were not applied and it is not clear how much flanking
sequence or other regions of the gene were investigated. It is
also unclear whether, once a mutation was identified, the
remaining gene regions were regularly and fully evaluated.
Many different kinds of mutation have been identified in
FBN1. Point mutations are the most common mutational
event, with nonsense and missense mutations comprising
about 10% and 60% of all reported mutations. The most
common missense mutations substitute cysteine residues
that form disulfide bonds within one of the cbEGF or 8-Cys
domains, but missense mutations creating novel cysteine
residues in these modules are also common. The majority of
the remaining mutations in these modules affect residues of
the calcium consensus sequence. About a quarter of missense
mutations affect modules other than cbEGF, and for the most
part, the pathophysiological mechanisms of these mutations
remain unclear.
Small insertions, deletions, or duplications represent about
13% of all reported mutations. The majority of these
mutations create a premature termination codon (PTC).
Another 13% of reported mutations consist of various classes
of splicing errors, most commonly affecting canonical splice
sequences at exon/intron boundaries. Many splice site
mutations in FBN1 result in in-frame exon skipping, such
that the mutant fibrillin-1 lacks an entire cbEGF domain.
Such mutations can be associated with a particularly severe
phenotype.
151 Some exon-skipping mutations in FBN1 result
in a frameshift
152 with reduced mutant RNA levels through
nonsense-mediated decay of the mutant transcript.
153 A
nonsense mutation
136 and a silent exonic mutation
154 in exon
51 have been reported as inducing in-frame skipping of the
entire exon 51 and demonstrate the existence of an exonic
splicing enhancer.
155 156
Global analysis of FBN1 mutations reveals two classes of
mutations. The first type, which represents more than one
third of the mutations, contains mutations predicted to result
in shortened fibrillin-1 molecules, including nonsense muta-
tions, splicing errors, insertions, and duplications, as well as
in-frame or out-of-frame deletions. These mutations are
likely to result in nonsense-mediated decay resulting in
reduction in the level of the mutant allele. The second type
represents slightly less than two thirds of the mutations and
contains missense mutations, mostly located in cbEGF-like
modules. They can be subclassified into: (a) mutations
creating or substituting cysteine residues potentially impli-
cated in disulfide bonding and consequently in the correct
folding of the monomer; (b) amino acids implicated in
calcium binding and subsequently in interdomain linkage,
structural integrity of affected domains, and increased
protease susceptibility; and (c) other mutations that might
affect the conformation of affected modules, interdomain
packing, or other functions such as protein-protein interac-
tions.
Elucidating the molecular basis of MFS and related
fibrillinopathies is the major goal of the teams working on
this subject.
149 157 The extreme clinical variability, the diffi-
culties associated with clinical diagnosis, and the low
detection rate of mutations in this large gene all conspire to
negatively impact on progress. At present it is not possible to
predict the phenotype for a given FBN1 mutation. On the one
hand, mutations affecting different positions within a given
module may be associated with quite different phenotypes.
Table 3 Type 1 fibrillinopathies
Syndrome Clinical features Reference
MFS See text See text
Neonatal MFS Severe end of clinical spectrum Kainulainen et al,
117 Booms et al
129
Atypically severe MFS Severe and early onset cardiovascular complications Putnam et al,
130 Tiecke et al,
131
Ectopia lentis Mainly ocular findings Lo ¨nnqvist et al,
132 Ades et al,
133
Kyphoscoliosis Progressive kyphoscoliosis of variable severity Ades et al
134
Familial arachnodactyly Dolichostenomelia and arachnodactyly Hayward et al
135
Familial thoracic ascending aortic See text
aneurysms and dissections
MASS phenotype Mitral valve prolapse, aortic dilatation without dissection, Dietz et al
136
skeletal and skin abnormalities
Shprintzen-Goldberg syndrome Craniosynostosis, a marfanoid habitus, and skeletal, Sood et al,
137 Kosaki et al
138 Robinson et al
139
neurological, cardiovascular, and connective tissue anomalies
Isolated skeletal features Tall stature, scoliosis, pectus excavatum, arachnodactyly Milewicz et al
50
New variant of MFS Skeletal features of MFS, joint contractures, ectopia lentis, Sta ˚hl-Hallengren et al,
140 Black et al,
141
no cardiovascular manifestations
Weill-Marchesani syndrome Short stature, brachydactyly, joint stiffness, and Faivre et al
142
(autosomal dominant) characteristic eye abnormalities
Although classic MFS is by far the most common disorder associated with FBN1 mutations, several other disorders with overlapping clinical findings have been
described due to mutations in FBN1.
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within two different modules may also be associated with
differing phenotypes. Therefore, it is apparent that neither
the location of the affected structural module in the protein
nor the position of the altered residue is, in itself, sufficient to
predict potential genotype-phenotype correlations.
158 The
high degree of intrafamilial variability suggests that environ-
mental and perhaps stochastic factors or modifying genes are
important for the phenotypic expression of disease. The level
of the expression of the normal fibrillin-1 allele
159 and
hyperhomocysteinaemia related to the C677T methylenete-
trahydrofolate reductase polymorphism
160 have been pro-
posed as factors that modify the clinical severity of MFS. The
elucidation of the full range of modifying factors in MFS
represents an interesting area for further research.
MUTATIONS IN TGFBR1 AND TGFBR2
Signalling by TGFb family cytokines controls a variety of
cellular processes including proliferation, differentiation, and
apoptosis; propagation of signalling into the cell is mediated
by a family of type 1 and type 2 receptors including the type 1
and type 2 TGFb receptor. TGFb binds first to type II
receptors, allowing subsequent incorporation of type I
receptors into a ligand-receptor complex involving a TGFb
dimer and four receptor molecules. The signal is then
propagated into the cell by means of phosphorylation of the
Smad proteins.
161
Linkage to chromosome 3p24.2–p25 was demonstrated for
a large family with a Marfan-like phenotype for whom
linkage to FBN1 and FBN2 had previously been excluded.
162 163
This disorder has been termed MFS type II (MIM 154705)
and shares some of the cardiovascular and skeletal features
of classic MFS.
Identification of a chromosomal breakpoint disrupting the
gene encoding the TGFb receptor 2 (TGFBR2) in a boy with
short stature, dural ectasia, and several skeletal and
cardiovascular manifestations of MFS led to the identifica-
tion of three further missense mutations in four families or
individuals with manifestations of MFS in whom FBN1
mutations had been ruled out (one mutation was found in
two unrelated families).
111 All the mutations were found in
the serine-threonine kinase domain of the TGFb receptor 2.
More recently, a new aortic aneurysm syndrome with
hypertelorism, bifid uvula or cleft palate, and generalised
arterial tortuosity with ascending aortic aneurysm together
with other findings such as craniosynostosis, mental retarda-
tion, and congenital heart disease was described; this
disorder, Loeys-Dietz aortic aneurysm syndrome (LDS;
MIM 609192), was shown to be associated with mutations
in the genes for either TGFb receptor type 1 or TGFb receptor
type 2 resulting in perturbations of TGFb signalling.
112 As will
be noted below, mutations of the arginine at position 460 of
TGFBR2 have been identified in individuals with thoracic
ascending aortic aneurysms and dissections (TAAD),
although there appears to be some degree of phenotypic
overlap with LDS in many affected individuals.
Microsatellite instability (MSI) is a prominent feature in
hereditary non-polyposis colorectal cancer (HNPCC) and
some forms of acquired colon cancer. Defects in mismatch
repair (MMR) genes and associated coding region MSI can
cause frameshift mutations with functional inactivation of
affected genes, thereby providing a growth advantage to
MMR deficient cells. TGFBR2 is one of the most commonly
affected genes with mutations in a polyadenine tract in exon
3 being found in up to 90% of cases of microsatellite-instable
sporadic and HNPCC associated colon cancer.
164 Germline
mutations in TGFBR2, however, are a rare cause of HNPCC.
165
Interestingly, one mutation (R528H) was found both as a
somatic mutation in colon cancer
166 167 and as a germline
mutation in LDS.
112 At present, there is no evidence that
individuals with LDS are at increased risk for colon cancer.
It should be noted that there has been some controversy as
to whether certain TGFBR2 mutations lead to a phenotype
that is identical or at least very similar to that of classic MFS,
thus justifying the diagnosis of type 2 MFS (MFS2). The
question about locus heterogeneity for MFS has been
addressed by several studies. Historical linkage data in MFS
families showed a cumulative LOD score for the FBN1 locus
in excess of 100, which provides evidence for a single
predominant locus for MFS. On the other hand, none of the
individuals with LDS
112 fulfilled the clinical diagnostic criteria
for MFS. In a previous study, Loeys et al
128 identified 86 FBN1
mutations in a cohort of 93 patients with classic MFS. None
of the remaining patients had a TGFBR2 or TGFBR1 mutation.
Overall, this suggests strongly that FBN1 is the predominant
if not sole locus for MFS.
128 However, there have been reports
of individuals with TGFBR2 mutations diagnosed with MFS2
without features characterising LDS.
168 Given that the
aneurysms in LDS appear to be more aggressive than those
in MFS and the fact that the cardiovascular involvement is
also characterised by arterial aneurysms throughout the
arterial tree and marked arterial tortuosity, it is clinically very
important to be aware of the potential differences between
these two syndromes. Detailed clinical characterisation of
individuals with TGFBR2 mutations will be required to
determine if a subset of these mutations is associated with
MFS2 or whether the diagnosis of LDS is more appropriate.
R522N
Cancer
LDS
Extracellular Protein kinase
del32–37
A(10): frameshift
L308P
T315M
Y336N
A355P
G357W
V387M V447A
N435S
L452M
R460
skipEx6 S449F
E526G
R528H
R528C
R528H
R537C
Figure 2 Mutations in TGFBR2 found in Loeys-Dietz aortic aneurysm syndrome (LDS)
112 and related hereditary disorders
111 113 and representative
missense mutations found in colon carcinoma
166 250 and breast carcinoma.
251 The TGFBR2 protein is drawn according to UniProt entry P37173 and
comprises an N-terminal signal sequence, an extracellular domain, a transmembrane domain (stippled rectangle), a cytoplasmatic region of unknown
significance (the white box), the serine-threonine protein kinase domain, and a C-terminal domain (black rectangle).
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CONTRACTURAL ARACHNODACTYLY
The discovery of a second fibrillin gene led to the genetic
association of fibrillin-2 encoded by FBN2 with congenital
contractural arachnodactyly (CCA). CCA or Beals syndrome
is characterised by a marfanoid habitus. In addition to the
tall, slender asthenic appearance, most individuals with CCA
have crumpled ears, flexion contractures, severe kyphosco-
liosis, and muscular hypoplasia.
169–172 The ear abnormalities
are characterised as a folded upper helix of the external ear.
In most patients, contractions of major joints (knees, elbows,
ankles) are present at birth. The proximal interphalangeal
joints display flexion contractures (that is, camptodactyly).
Contractures of the hip, adducted thumbs, and clubfoot may
also occur. Bowed long bones and muscular hypoplasia are
additional musculoskeletal findings in CCA. Contractures
usually resolve with time. Arachnodactyly (long slender
fingers and toes) is present in most individuals with CCA.
The greatest morbidity in CCA is caused by progressive
kypho/scoliosis that can begin in early infancy. It is present in
about half of all affected individuals. The spinal abnormalities
are progressive. Severe thoracic cage abnormalities with
associated scoliosis may cause restrictive pulmonary disease.
173
While CCA shares some clinical characteristics with MFS
(table 4), it does not share the usually shortened life expectancy.
Putnam et al
110 were the first to identify mutations in two
unrelated individuals with CCA; both were cysteine substitu-
tions. It is important to note that in contrast to the
distribution of FBN1 mutations causing MFS throughout
the coding region, the FBN2 mutations so far identified in
CCA appear to cluster between exons 23 and 34. The
homologous region of FBN1, the so called neonatal region,
contains the greatest percentage of mutations from MFS
patients at the most severe end of that disorder’s clinical
spectrum.
117 Virtually all of the known FBN2 mutations are of
the calcium binding epidermal growth factor-like (cbEGF)
domains.
174–178
Molecular studies of only one individual with severe/lethal
CCA have been performed.
179 This individual had an exon
splicing mutation that caused the skipping of exon 34, a
cbEGF-like domain. Significantly, this individual’s mother
was a somatic mosaic with one third of her fibroblasts also
harbouring the same exon 34 mis-splicing mutation.
Therefore, one can speculate that there is a threshold for
certain mutations causing skeletal perturbations versus
severe developmental abnormalities in the cardiovascular
and gastrointestinal systems.
Although individuals with CCA usually do not have aortic
involvement, aortic root dilatation does occur in some cases
and screening for aortic involvement should be performed in
individuals with this disorder.
180
Fibrillin-2 in development and animal models
The temporal and spatial expression of fibrillin-2 has been
examined in several species. In human fetal aorta, antibodies
to fibrillin-2 were found to stain most intensely in the media,
where elastic fibres are most abundant. In human elastic
cartilage, fibrillin-2 localised to the cartilaginous core while
fibrillin-1 localised primarily to the surrounding connective
tissue.
4 Fibrillin-1 and fibrillin-2 demonstrate a similar
spatial and temporal distribution in most tissues during
early human embryonic development. Exceptions included
the kidney, liver, rib anlagen, and notochord.
181 Similar
studies in the developing mouse showed that in most tissues
fibrillin-2 was expressed earlier than fibrillin-1.
182
Studies in the chick have shown that fibrillin-2 (called JB-
3 in the early literature) is expressed very early in develop-
ment and is found in the regions of heart development.
183 The
early expression of the fibrillins has led to speculation that
they may mediate the tensile forces that shape the early
embryo.
184 A possible role for fibrillin-2 in lung development
has been shown in a rat model. Studies of fetal lung explants
demonstrated abnormal branch morphogenesis when the
explants were incubated with antisense oligonucleotides to
fibrillin-2.
185
Browning et al
186 described a mouse with syndactyly (sne)
that was derived from chemical mutagenesis of murine
embryonic stem cells. They showed that sne (now renamed
sy
fp-3J) was an allele of the sy locus. sy is the shaker-with-
syndactylism mouse, a radiation mutant with a chromosome
18 (syntenic to human chromosome 5) contiguous gene
deletion syndrome.
187 The deleted region contains the gene
encoding fibrillin-2. Some spontaneously occurring mouse
models with syndactyly also mapped to the sy locus (sy
fp and
sy
fp-2J). All three sy
fp mutations are FBN2 mutations.
186 188
Additional evidence that absence of FBN2 leads to syndactyly
came from gene targeting studies.
12 The FBN2
2/2 knockout
mouse displayed the same type of syndactyly observed in the
sy mice. Interestingly, two of the fibrillin-2 mutations in the
sy
fp mice were outside the neonatal region, that is, the area in
which all of the human CCA mutations have been found.
188
These findings have led to the obvious speculation that
fibrillin-2 mutations outside the neonatal region, for exam-
ple, may lead to other human phenotypes.
188
FAMILIAL THORACIC ASCENDING AORTIC
ANEURYSMS AND DISSECTIONS
Cystic medial necrosis (CMN) is known to be associated with
syndromes such as MFS, but is more frequently found in the
absence of an associated phenotypic syndrome. Reports of
families with autosomal dominant inheritance of thoracic
aortic aneurysms leading to type A dissections (TAAD) with
medial necrosis on pathologic examination indicate that
single gene mutations can cause medial necrosis in the
absence of an associated syndrome.
189 190 Additionally, medial
necrosis of the proximal aorta with aneurysms/dissections is
associated with other heritable diseases such as Turner
syndrome,
191 Noonan syndrome,
192 Ehlers-Danlos syn-
drome,
193 patent ductus arteriosus,
194 195 and bicuspid aortic
valve.
196 197
Initial studies showed that first degree relatives of
probands with non-syndromic TAAD have a higher risk of
thoracic aortic aneurysms and sudden death compared with a
control group.
198 199 In addition, these studies support the
hypothesis that genetic factors play a role in the aetiology of
TAADs in patients who do not have an identified syndrome
causing aortic disease. Milewicz and colleagues described six
families with aortic aneurysms and dissections, all of whom
demonstrated autosomal dominant inheritance associated
with decreased penetrance and variable age of onset of the
aortic disease.
189 Various studies indicate that the aortic
disease in the majority of these families is not due to a
mutation in the FBN1 gene or other genes encoding vascular
proteins, such as COL3A1.
189 200 201
More recently, several loci for non-syndromic TAAD have
been mapped. The first locus, termed TAAD1, was mapped to
chromosome 5q13–14 with a maximum LOD score of 4.74
Table 4 Clinical features of congenital contractural
arachnodactyly
Marfanoid habitus
Flexion contractures of multiple joints including elbows, knees, hips,
fingers
Kyphoscoliosis (sometimes severe)
Muscular hypoplasia
Abnormal pinnae (presenting as crumpled outer helices)
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202 This locus was confirmed by an
independent study in a Finnish population where approxi-
mately one half of the families studied show evidence of
linkage to TAAD1.
203 The critical interval containing the
defective gene maps to a 7.8 cM region. Another locus for
familial aortic aneurysms and dissections has been mapped
to the long arm of chromosome 11 (11q23–24) using a single
large family.
204 In contrast to the families linked to TAAD1,
the clinical phenotype of the family linked to the FAA1 locus
indicated a diffuse vascular aetiology. Apart from dilatation
in the sinuses of Valsalva, involvement of other aortic
segments and arteries was also observed, such as dilatation
in the abdominal aorta and left subclavian artery. In addition,
the disease was fully penetrant with aortic imaging in the
family described. The FAA1 locus is a rare cause of the
vascular condition as indicated by the fact that no other
families demonstrate linkage of the phenotype to markers at
this locus.
Another locus for TAAD was mapped to a 25 cM region on
chromosome 3p24–25 using another large family with
multiple members with aneurysms and dissections of the
thoracic aorta. The disease in the family was characterised as
autosomal dominant with decreased penetrance and variable
age of onset.
205 Eighteen TAAD families described previously
failed to show linkage to 3p24–25, indicating that TAAD2 is a
minor locus for TAAD.
202 204 It was recently determined that
mutations in the transforming growth factor beta receptor
type II gene (TGFBR2) is the cause of disease at the TAAD2
locus.
113 The TGFBR2 gene was screened for missense,
nonsense, and exon splicing errors and mutations were
found in four out of 80 unrelated families with familial
TAAD, indicating that TGFBR2 mutations are a relatively rare
cause of familial TAAD. Although most vascular disease in
these families involved ascending aortic aneurysms leading to
type A dissections, affected family members also had
descending aortic disease and aneurysms of other arteries,
including cerebral, carotid, and popliteal aneurysms.
Strikingly, all four families carried mutations that affected
arginine at amino acid 460 in the intracellular domain,
suggesting a mutation hot spot for familial TAAD and
establishing a strong genotype-phenotype correlation
between familial TAAD and mutations at this location.
Structural analysis of the TGFBR2 serine/threonine kinase
domain reveals that R460 is strategically located within a
highly conserved region of this domain and that the amino
acid substitutions resulting from these mutations will
interfere with the receptor’s ability to transduce signals. A
surprising observation in these families was that there is no
evidence of an increased susceptibility to cancer in families
with germline TGFBR2 mutations, despite evidence in the
literature that somatic TGFBR2 mutations occur in a variety
of cancers.
In summary, TAAD is a genetically heterogeneous disease
that may be inherited in conjunction with a syndrome or as a
non-syndromic predisposition for TAAD. Studies of familial
TAAD due to TGFBR2 mutations have highlighted the
dysregulation of the TGFb pathway as a mechanism leading
to aneurysm formation. Clinically, it is important to perform
cardiovascular evaluation on first degree relatives of indivi-
duals with suspected non-syndromic familial aortic dissec-
tion, because of the possibility of potentially life-threatening
vascular disease in an individual with obvious phenotypic
signs of the disorder.
THE EFFECTS OF FIBRILLIN MUTATIONS ON THE
STRUCTURE OF FIBRILLIN-1 DOMAINS
In order to understand the effects of fibrillin mutations on
the structure and function of the tissues affected by MFS, it
will ultimately be necessary to understand the effects of
mutations on protein structure. It has not been possible to
determine the structure of the entire fibrillin-1 protein or
even of larger fragments thereof. However, studies on
recombinant polypeptides comprising up to several cbEGF
or 8-Cys modules have provided significant insight.
The two predominant structural modules in fibrillin-1 are
the calcium-binding epidermal growth factor-like domain
(cbEGF) and the transforming growth factor b binding
protein-like (TB or 8-Cys) domain. High resolution structures
of the fibrillin-1 domain fragments cbEGF32–33, TB6, and
cbEGF12–13 have been solved previously using nuclear
magnetic resonance (NMR) which identifies the solution
structure of the molecule.
17 35 206 More recently, x ray crystal-
lography has been used to solve the structure of the triple
domain fragment, cbEGF22-TB4-cbEGF23
36 and demon-
strated a calcium-stabilised tetragonal pyramidal conforma-
tion. An RGD integrin binding site localises to the tip of a b-
sheet within TB4 and is thus accessible to cell-surface
integrins. Comparative sequence alignments of the linker
regions from cbEGF-TB domains within fibrillin-1 suggest
that the relative orientation of cbEGF22-TB4 is likely to be
preserved at homologous sites within fibrillin-1. In contrast,
the variation in amino acid number and composition of TB-
cbEGF linker sequences suggests that these pairs will adopt
different orientations with respect to one another within
fibrillin-1, and may contribute to the biomechanical properties
of microfibrils. This is supported by the variability of Kd values
of TB-cbEGF pairs from fibrillin-1 (see below). A model of a
large region of fibrillin-1 (cbEGF11-TB5) has been generated
from this combined structural information, which suggests
that although the protein is in an extended conformation, it is
not simply linear. A significant bend is introduced by the
packing of cbEGF22 against TB4. Based on this structure, a
staggered model for assembly of fibrillin-1 into the microfibril
has been suggested as an alternative to the proposed
organisation based on electron microscopic studies.
36
Single cbEGF domains expressed from fibrillin-1 and other
proteins usually display low affinity binding in the mM
range. However, in fibrillin-1, and in many other proteins,
the cbEGF domains are often arranged as repeating tandem
arrays. On covalent linkage of an N-terminal cbEGF, the
affinity of the C-terminal cbEGF increases.
207 The bound
calcium, together with the hydrophobic packing interaction,
performs a key structural role in restricting interdomain
flexibility
35 208 and therefore protects the modules against
proteolytic cleavage.
209 210 Dynamics studies show that the
most stable region of a cbEGF pair is in the vicinity of the
interdomain calcium-binding site.
208 Analysis of different
cbEGF domain pairs has, however, identified a range of
affinities from 350 mM to 300 nM, suggesting that primary
sequence variation, in addition to the pairwise domain
interaction, must also influence affinity.
211 212 A study of
heterologous TB-cbEGF domain pairs
37 has shown that most
of these domain pairs bind Ca
2+ considerably more tightly
than previously observed, with Kd values as low as 9 nM.
These data suggest that under physiological conditions, many
fibrillin-1 cbEGF domains will be fully saturated and may
impart rigidity to the native protein. However, the TB6-
cbEGF32 domain pair, with a Kd of 1.6 mM,
213 appears the
most likely of the TB-cbEGF domain pairs to be flexible and
may contribute to the extensibility and elasticity of the
microfibrils.
Insights into the role of a number of disease-causing FBN1
mutations in the pathogenesis of MFS have been gained from
NMR, calcium chelation, and limited proteolysis studies of
recombinantly expressed fragments of fibrillin-1. Reduction
of calcium binding caused by substitution of a calcium ligand
or destabilisation of the interdomain interface would be
predicted to produce a less extended, more flexible structure
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proteolytic susceptibility due to exposure of enzyme-specific
cryptic cleavage sites. The effect of a missense mutation on
protease susceptibility of a cbEGF domain can, however, be
influenced by a number of factors such as the particular
residue mutated and the position of the mutant domain
within the fibrillin-1 peptide.
The structural effects of the pathogenic mutations C1977Y
and C1977R which disrupt the 1–3 disulphide bond of
cbEGF30 and are therefore predicted to cause misfolding,
have been studied in a cbEGF29–31 triple construct using the
combined methods of NMR, chelation, and limited proteo-
lysis.
212 The substitutions caused loss of Ca
2+ binding to
cbEGF30, consistent with intradomain misfolding and
disrupted cbEGF29–30 domain-domain packing.
Surprisingly, the calcium binding properties of cbEGF29
and cbEGF31 were unaffected, suggesting these cysteine
substitutions have relatively localised effects confined to the
N-terminal end of the mutant domain (fig 3A). However, a
disruption of the 5–6 disulphide bond by a C750G substitu-
tion which affects the C-5 residue of cbEGF7 in an EGF4-TB3
fragment caused increased proteolytic susceptibility of
cbEGF8.
214 This is presumably due to disruption of domain
packing between cbEGF7 and 8 and hence reduction of the
calcium binding affinity of cbEGF8. Cysteine substitutions
are therefore likely to have different structural effects, which
depend on the particular disulphide bond affected, and hence
result in a variety of pathogenic mechanisms.
These studies, together with earlier reports, emphasise the
structural heterogeneity that can be introduced into fibrillin-
1 by different FBN1 mutations. In the case of the folding
substitution, G1127S, in cbEGF13, it was shown
215 216 that the
mutant domain retained the ability to bind calcium (fig 3B).
Studies
210 213 of the effects of the calcium binding substitu-
tion, N2144S, in domain pairs demonstrated that, while the
structure of the mutant domain was unaffected, its ability to
bind Ca
2+ was reduced (fig 3C). Calcium binding substitu-
tions which occur in the context of a cbEGF domain pair can,
however, result in more significant structural changes.
210 217
For example, the protein engineered N2183S substitution in
cbEGF33 (fig 3D) resulted in an increased proteolytic
susceptibility of the cbEGF32–33 domain pair and the lack
of calcium dependent protection indicated the absence of
Ca
2+ binding to the mutant domain.
210 Thus, as with cysteine
substitutions, calcium-binding substitutions may cause vari-
able intramolecular effects dependent upon domain context.
It is evident that the structural effects of different FBN1
missense mutations are complex. In the neonatal region of
fibrillin-1, for example, missense mutations which affect
structurally analogous calcium ligands in different cbEGF
domains or cause substitution of different ligands coordinat-
ing the same Ca
2+ (D1113G and N1131Y) produce varying
phenotypes. Three missense mutations, K1043R, I1048T, and
V1128I, which have no clear structural effect (although the
I1048T substitution does introduce a glycosylation consensus
sequence) are found to cluster on one face of a model
constructed for the cbEGF11–15 region of fibrillin-1. An
unstructured, extended loop, present in cbEGF12 between
cysteines 5 and 6, may also localise to this face of the model
and be involved in intra- or intermolecular contacts.
206
Analysis of the model shows that substitutions that may
affect the calcium-binding properties of cbEGF12 give rise to
severe phenotypes. An increase in the intrinsic flexibility of
this region resulting from defective calcium binding could
distort a potential binding interface, which may be important
for the microfibril assembly process and/or interactions with
other microfibril components.
A correlation between the in vitro structural effects of
amino acid substitutions with their cellular behaviour and
consequences for intracellular trafficking and secretion is
important for understanding the pathogenesis of MFS.
Fibrillin-1 biosynthesis, processing, and matrix deposition
have been studied by pulse-chase analyses of patient
fibroblast cell cultures.
44 45 218 The interpretation of such
pulse-chase studies, however, is complicated by the presence
of normal fibrillin-1 produced from the wild type allele,
which cannot be distinguished from the mutant product. In
order to study the fate of mutant fibrillin-1, a recombinant
system has been developed using a fibroblast host cell.
219
In this system, fibrillin-1 fragments containing two
cysteine substitutions associated with classic MFS, C1117Y
and C1129Y in cbEGF13, were retained intracellularly in the
endoplasmic reticulum when expressed as a shortened form
(100 kDa) of fibrillin-1. This suggests that the delay in
secretion observed in the patient cells is due to selective
retention of mutant protein in the cell. In contrast, the
G1127S folding substitution in the same domain was
secreted into conditioned medium. This, together with the
pulse-chase studies of patient fibroblasts containing G1127S,
which showed normal synthesis and secretion of fibrillin-1
but reduced deposition in the extracellular matrix, suggests
cbEGF31 cbEGF30
C1977R/Y
cbEGF29 A
cbEGF14 cbEGF13
G1127S
cbEGF12 B
cbEGF32
N2144S
TB6 C
cbEGF33 cbEGF32
N2144S
cbEGF33 cbEGF32
N2183S
D
Figure 3 Schematic illustration of the variable effects of missense
mutations on calcium binding in multi-domain fragments from fibrillin-1.
Calcium binding properties were assessed by NMR, limited proteolysis,
and (for A) calcium chelation. Bound calcium is depicted as a grey circle
and the absence of detectable binding as an open circle. The grey
diagonal striped circle indicates reduced binding.
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effect during or after incorporation of fibrillin-1 into the
microfibril. A greater disruption to cbEGF13 presumably
results from the presence of an unpaired cysteine than from
the localised structural effects of G1127S. Mutant proteins
retained as a consequence of misfolding may result in
functional haploinsufficiency or, alternatively, have an
intracellular dominant negative effect. These functional
studies of the structural changes introduced by missense
mutations provide further insights into the pathogenic
mechanisms leading to MFS.
FBN1 MUTATIONS AND PROTEOLYSIS
Most FBN1 missense mutations reported to date affect one of
the highly conserved cysteine residues or a residue of the
calcium-binding consensus sequence in one of the 43 cbEGF-
like modules.
149 Such mutations are predicted to reduce the
calcium affinity of affected modules, which has been
experimentally verified in a number of cases.
212 213 220 221 On
the other hand, calcium-binding is important for the stability
of cbEGF modules in a variety of ECM proteins such as
fibrillin-1,
209 222–224 and removal of calcium by incubation leads
to an increase of susceptibility to proteolysis.
209 225–227 These
findings have motivated several groups to investigate the
effects of FBN1 mutations on the susceptibility of recombi-
nant fibrillin fragments.
A number of FBN1 mutations have been shown to increase
the susceptibility of recombinant fibrillin-1 polypeptides to in
vitro proteolysis (table 5). Many of the FBN1 mutations
investigated in in vitro assays to date are predicted to reduce
the calcium binding affinity of the cbEGF module harbouring
the mutation. It has been shown by methods including two-
dimensional NMR spectroscopy
216 and N-terminal sequencing
of mutant polypeptide proteolytic fragments,
217 that FBN1
mutations can cause short and long range conformational
deformations. The fact that FBN1 mutations can produce
protease-sensitive sites can be explained by reduced steric
hindrance for the proteases caused by a missing calcium ion
or other conformational changes.
217 The molecular effects of
calcium-binding mutations may be influenced by the
calcium-binding affinity of affected cbEGF modules and by
the location of the cbEGF module in the protein as well as the
neighbouring modules.
210 This, as well as the observation that
different mutations within one cbEGF module can have a
differential effect on susceptibility to proteolysis,
228 provides
potential explanations for some genotype-phenotype correla-
tions in MFS. Two mutations affecting the 1–3 disulfide bond
of cbEGF30 of fibrillin-1 had structural effects localised to the
N-terminal end of the mutant domain, with impaired domain
packing with the preceding module.
212 On the other hand,
C750G, which affects the 5–6 disulfide bond of cbEGF7,
increases proteolytic susceptibility of cbEGF8.
214
These data can be interpreted to mean that both the
residues affected, the localisation within the cbEGF module,
the localisation within the polypeptide chain of fibrillin-1,
and the nature of the neighbouring residues and the strength
or flexibility of interdomain linkages all can be important for
determining the effects of FBN1 mutations on proteolytic
susceptibility.
While the above observations suggest that proteolysis may
play a role in the pathogenesis of MFS, it should be noted
that there is no formal proof of this available at the moment.
Assuming that increased susceptibility to proteases does play
a role in the pathogenesis of MFS, then there are at least two
mechanisms that could be important. Proteolytic degradation
of mutant fibrillin-1 monomers could take place following
secretion into the extracellular space but before incorporation
into the microfibrils, thus reducing the total amount of
fibrillin-1 available for assembly of microfibrils. Alternatively,
mutant fibrillin-1 monomers could be incorporated into
microfibrils and then represent a sort of Achilles’ heel
causing increased susceptibility of the entire microfibrillar
structure to proteolysis and fragmentation.
229 These issues, as
well as a formal demonstration of the presence of fibrillin-1
proteolytic fragments in tissues of MFS patients, represent
potentially fruitful areas for future research.
Upregulation of matrix metalloproteinase expression
by fibrillin fragments
The above observations suggest that FBN1 mutations might
increase the susceptibility of entire microfibrils to proteolytic
degradation, which could in turn lead to fragmentation of
microfibrils in affected tissues. This hypothesis appears
plausible because there is evidence of microfibrillar fragmenta-
tion in tissues of MFS patients
230 and increased matrix
metalloproteinase (MMP) concentrations in tissues of MFS
patients,
231 232andfibrillin-1 is susceptible todigestion by several
MMPs.
233 On the other hand, ECM proteins can influence
cellular function and gene regulation by outside-to-inside
signalling,
234 and in some cases, fragments of ECM proteins
acquire novel signalling properties that the intact molecules do
not possess.
235 For instance, increased concentrations of
fibronectin fragments are found in osteoarthritis and can
themselves upregulate the expression of several MMPs.
236 237
A recent study showed that a recombinant fibrillin-1
polypeptide containing the integrin binding RGD site of
fibrillin-1 can upregulate the expression and production of
MMP-1 and MMP-3 in a cell culture system.
238 Ad i f f e r e n t
recombinant fibrillin-1 fragment containing a putative GxxPG
elastin-bindingprotein(EBP)interactionmotifupregulatesthe
expression and production of MMP-1 by a factor of up to 9, an
effect that was abolished by a mutation of the GxxPG
consensus sequence.
239 These observations provide a plausible
explanation for the increased MMP concentrations seen in the
tissues of MFS patients and suggest also the possibility of a
vicious cycle whereby the constant presence of fibrillin-1
fragments could lead to increased MMP production which in
turn could cause the production of more fibrillin-1 frag-
ments.
228 Additionally, since TGFb1 can increase expression of
several MMPs,
240 increased protease-mediated TGFb release
could further add to the proposed vicious cycle.
It has recently been shown that aortic extracts of the
fibrillin-1 underexpressing mgR/mgR MFS mouse model, as
well as a recombinant fibrillin-1 fragment containing a
GxxPG EBP interaction motif, can stimulate macrophage
chemotaxis, an effect that was significantly diminished by
Table 5 FBN1 mutations identified in individuals with
MFS that have been shown to increase susceptibility to in
vitro proteolysis
Mutation Location Reference
N548I cbEGF4 Reinhardt et al
217
R627C cbEGF6 Vollbrandt et al
214
C750G cbEGF7 Vollbrandt et al
214
E1073K cbEGF12 Reinhardt et al
217
G1127S cbEGF13 Whiteman et al
216
K1300E cbEGF17 Booms et al
228
C1320S cbEGF17 Booms et al
228
D1406G cbEGF20 Robinson and Booms
229
C1408F cbEGF20 Robinson and Booms
229
C1977R cbEGF30 Suk et al
212
C1977Y cbEGF30 Suk et al
212
N2183S cbEGF33 McGettrick et al
210
The predicted amino acid change and the affected cbEGF modules are
shown. Note that N2183S is a protein-engineered mutation and has not
been found in patients.
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elastin-derived peptide VGVAPG, and by a mutation of the
EBP recognition sequence in the fibrillin-1 fragment,
indicating involvement of EBP in mediating the effects
(Gao and Robinson, under review). Additionally, investiga-
tion of macrophages in aortic specimens of Marfan patients
demonstrated macrophage infiltration in the tunica media.
These findings provide a plausible molecular mechanism for
the inflammatory infiltrates observed in the mgR mouse
model and suggest that inflammation may represent a
component of the complex pathogenesis of MFS. Further
work will be necessary to determine if inflammation and
alterations of MMP regulation contribute in a significant way
to the initiation or progression of disease.
GENETICS OF MFS IN MOUSE MODELS
Creation of genetically engineered mouse models of MFS has
been instrumental in modifying our long-held belief that
MFS is a classic dominant-negative disorder, in which the
abnormal protein derived from the mutant allele functionally
neutralises the normal protein produced from the wild type
allele. These animal studies have revealed unsuspected
functions of extracellular microfibrils in orchestrating cellular
activities and morphogenetic programs through the modula-
tion of critical signalling events. Most importantly, they have
opened exciting new opportunities for the development of
productive treatment strategies in MFS, in addition to
implicating dysregulated TGFb signalling in the genesis of
other developmentally and postnatally acquired elastin-
deficient states.
The first new insight regarding the pathogenesis of
cardiovascular disease derived from the study of mouse
strains homozygous for hypomorphic (low expressing)
fibrillin-1 (Fbn1) alleles. They included the mgD/mgD mice,
which express a centrally deleted protein at about 5% of the
normal level and die shortly after birth, and mgR/mgR mice,
which express full length protein at about 15% of the normal
level and die at 3–6 months of age.
10 11 241 That mgD/mgD
mice exhibit only focal disruptions in elastic fibre organisa-
tion demonstrated that minimal (if any) residual microfi-
brillar function is sufficient to support the deposition of
extended elastic structures.
10 On the other hand, the longer
life span and normal aortic wall architecture of mgR/mgR
mice allowed demonstration of the pathogenic sequence that
culminates in aneurysm in these animals.
11 The secondary
events include regional elastic fibre calcification, intimal
hyperplasia, and adventitial inflammation, findings that were
generally spatially coincident and which were subsequently
confirmed in MFS patients as well.
241 Loss of physical
connections between vascular smooth muscle cells and
neighbouring elastic fibres that are normally mediated by
fibrillin-1 are believed to contribute to the initiation of this
destructive process.
241 As a result, the morphology and
synthetic program of the cells are altered, perhaps in an
abortive attempt to reconstitute a normal extracellular
environment, and the ensuing remodelling process is
characterised by overproduction of multiple structural matrix
components and mediators of elastolysis, including MMPs 2
and 9.
241 Subsequent breach of the internal or external elastic
laminae allows infiltration of inflammatory cells into the
media, resulting in intense elastolysis that correlates tempo-
rally with aneurysm formation and dissection. The critical
insights derived from this work are that a normal comple-
ment of fibrillin-1 is needed for elastic fibre homeostasis
rather than formation, and that there may be important
opportunities to alter the natural history of disease through
modification of secondary events including inflammation
and matrix destruction.
Haploinsufficiency contributes to disease progression
The above data suggested a threshold hypothesis, whereby
the relative abundance of functionally competent fibrillin-1
microfibrils determines the clinical severity of the MFS
phenotype. Consistent with this postulate, recent evidence
indicated that half-normal production of wild type fibrillin-1
(haploinsufficiency) can contribute to reaching the threshold
loss of microfibril function needed for clinical expression of
MFS.
242 First, transgenic overexpression of mutant protein, in
the context of two normal Fbn1 alleles, was insufficient to
cause the vascular changes of MFS seen in mice heterozygous
for a comparable missense mutation (C1039G). Second, mice
heterozygous for a null Fbn1 allele showed similar alterations
in aortic wall architecture as Fbn1
C1039G/+
mice. Finally, the
transgenic addition of an additional wild type allele to
C1039G mice rescued the aortic phenotype. Thus, a normal
complement of fibrillin-1 may be needed to initiate produc-
tive microfibrillar assembly.
242 While the haploinsufficiency-
imposed reduction in microfibril abundance may or may not
be sufficient, in isolation, to lead to classic MFS, it appears
critical to the context within which a dominant negative
effect can achieve clinical significance. These data raised the
possibility that boosting fibrillin-1 expression may be a
productive therapeutic strategy and thus offered attractive
hypotheses regarding the role of genetic modifiers in the
modulation of disease severity.
Microfibrillar modulation of signalling molecules
More recent observations have indicated that microfibril-
associated disorders are actually developmental abnormal-
ities that affect multiple morphogenetic programs and
become clinically manifest later in life.
12 243 244
Multifunctional molecules that are secreted into the extra-
cellular space and which signal through membrane-bound
receptors are the primary triggers and modulators of cellular
activities underlying development and growth, and tissue
homeostasis and repair.
245 Findings in fibrillin deficient mice
have implicated the participation of extracellular microfibrils
in TGF/BMP signalling events that control patterning and
morphogenesis. In turn, these results have suggested func-
tional coupling between tissue-specific organisation of elastic
fibre macroaggregates, and their ability to perform instructive
as well as structural functions.
The first evidence implicating fibrillin-rich microfibrils in
developmental process derived from the finding that fibrillin-2
(Fbn2) mice display bilateral syndactyly, as a result of failed
BMP-induced apoptosis of the prospective interdigital
mesenchyme.
12 The patterning defect was associated with
altered microfibril assembly only and specifically in the
developing autopod, and with loss of interdigital tissue
competence to respond to apoptotic cues from exogenously
administered BMP signals. Importantly, the combination of
Fbn2 and Bmp7 haploinsufficiency, which are by themselves
phenotypically silent, resulted in impaired digit formation in
the absence of additional manifestation. These data therefore
suggested that the tissue-specific architecture of fibrillin-rich
microfibrils may positively regulate BMP signalling by con-
centrating effector molecules at the site of intended function.
The other evidence for a direct role of the fibrillins in the
regulation of signalling molecules derived from the study of
lung disease in mgD and mgR mice.
243 A distinct subset of
individuals with MFS have clinically manifest lung disease,
generally presenting as spontaneous pneumothorax, and
even more of them show radiographic evidence of obstructive
lung disease, including upper lobe bullae and/or more diffuse
airspace widening.
246 247 Such findings have been traditionally
reconciled with models that invoke structural failure of the
connective tissue with subsequent inflammation and
destructive emphysematous changes. However, mgD/mgD
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saccules without any evidence of inflammation or tissue
destruction.
243 Instead, a dramatic paucity of primordial
alveolar septa was the predominant finding, suggesting a
primary developmental failure of distal alveolar septation
rather than classic emphysema, as previously inferred.
Failure of lung septation in the mutant mice was correlated
temporally and spatially with excess immunoreactive free
TGFb resulting from increased local activation rather than
production and secretion of the cytokine.
243 More impor-
tantly, TGFb neutralising antibodies rescued lung morpho-
genesis in mgD/mgD mice. These results raised the possibility
that a similar mechanism may underlie other manifestations
of MFS, including bone overgrowth, valve changes, and
aortic dilatation.
243 Indeed, myxomatous changes of the
mitral valve in Fbn1
C1039G/+
mice were recently correlated
with excess TGFb signalling and were prevented by TGFb
antagonism in vivo.
244
Dysregulated TGFb signalling in MFS-like conditions
A recent report suggested heterozygous loss of function
mutations in the type II TGFb receptor (TbRII) phenocopy
MFS.
111 Selected mutant receptors were shown to be
incapable of propagating TGFb signal when expressed in
cells naive for TbRII. A subsequent report suggested that the
phenotype associated with heterozygous mutations in either
TbRI or TbRII is distinct from MFS, but shows some overlap
including aortic aneurysm, arachnodactyly, pectus defor-
mity, and scoliosis.
112 Highly prevalent distinguishing
features included cleft palate/bifid uvula, hypertelorism,
and arterial tortuosity; more variable features included
craniosynostosis, neurocognitive abnormalities, and conge-
nital heart disease. Importantly, heterozygous patient cells
showed full preservation of the acute phase response to
TGFb while patient-derived tissues showed evidence of
increased (rather than decreased) TGFb signalling.
112 While
adding to the complexity, these data support the conten-
tions that many features of microfibril disorders likely
manifest failure of proper regulation of cytokine function,
and that consideration of both primary and secondary
events will be required to attain full mechanistic insight.
Efforts are underway to comprehensively evaluate the utility
of TGFb antagonism in the treatment of the multisystem
manifestations of MFS, an initiative that will require both
animal studies and multicentre collaborative human clinical
trials. There is particular attractiveness for consideration of
the use of angiotensin II type I receptor blockers, such as
losartan, that both lower blood pressure (a known positive
effect in MFS) and lead to a clinically relevant attenuation
of TGFb signalling.
CONCLUSIONS
The past 5 years have witnessed remarkable progress in
elucidating the anatomy and physiology of the microfibrils
and in understanding the pathogenesis of MFS on a
molecular level. In particular, our understanding of the
pathophysiology of MFS has evolved away from previous
more or less static concepts involving a dominant negative
mechanism resulting in structural weakness of connective
tissue.
A full understanding of the pathogenesis of MFS will
require further advances in many different areas. We are
beginning to understand a range of pathophysiological
processes involving protein folding and stability, microfibril-
lar assembly, proteolysis of mutant fibrillin monomers,
secondary effects of fragmentation, loss of smooth muscle
cell attachments, and alterations in TGFb signalling. The
challenge for the coming years will be to sort out the relative
contributions of these defects to the pathogenesis of the
various manifestations of MFS. There is no reason to believe
that the molecular pathogenesis of ectopia lentis must be the
same as that of long bone overgrowth or aortic dissection,
and indeed the fact that the various manifestations of MFS
do not always occur together in the same patient suggests
that there may be important differences in detailed patho-
genetic mechanisms.
We still do not know enough about the molecular
mechanisms in MFS to develop a model that would explain
the sequence of events leading from a mutation in FBN1 to
clinical disease. Clinical observations and experimental
studies using in vitro systems, cell culture models, or
animal models have demonstrated multiple abnormalities,
but it is not entirely clear how the sequence of pathogenetic
events seen in MFS occurs. One interpretation of the
available evidence is that FBN1 mutations lead to either a
microfibrillar assembly defect with reduced levels of
fibrillin-rich microfibrils in tissues, or that mutant fibrillin
monomers are incorporated into microfibrils and cause a
slow but progressive loss of microfibrils. By whatever
mechanism this occurs, the loss of fibrillin-rich microfibrils
then has a series of other secondary effects, including a
disturbance of the ability to sequester TGFb and modulate
its activity appropriately. Disturbances in the ability of
microfibrils to adequately sequester other growth factors
may also be important. Increased levels of MMPs may be a
result of increased TGFb activity, of phenotypic alteration of
vascular smooth muscle cells owing to loss of cell attach-
ments that are normally mediated by fibrillin-1, or of effects
of the fibrillin fragments themselves. Other secondary
effects of fibrillin or elastin fragments could include
recruitment of macrophages into the aortic wall by
chemotactic stimulation, which could contribute to further
progression of aneurysm formation.
The study of mutations and genotype-phenotype correla-
tions in MFS and related disorders may provide clues that
will help elucidate the above issues. At present, there are no
plausible molecular explanations for most of the genotype-
phenotype correlations that have been observed with FBN1
mutations. For instance, we are not able to explain why a
mutation in exon 59 is associated with isolated ectopia
lentis
132 and why other mutations are associated with the
severe neonatal form of MFS.
129
Although our knowledge of the molecular pathogenesis of
MFS is still incomplete, the new paradigms emerging from
recent studies have the potential to improve treatment for
individuals with MFS. The most promising new direction is
the pharmacological manipulation of the TGFb signalling
pathway with angiotensin II type 1 receptor blockers such as
losartan, which both lowers blood pressure and attenuates
TGFb signalling.
248
Although judgments concerning the usefulness and
indications of losartan will have to await the results of
clinical trials, it does appear certain that our current
understanding of MFS as a no-longer purely structural
disorder of the matrix will reveal new molecular targets that
can be exploited pharmacologically to improve the lives of
individuals with this disorder.
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